As competition intensifies, success in oncology dealmaking depends on disciplined focus, speed and strategic positioning.
Oncology dominates global biopharma BD&L, with rising deal values and growing innovation from new modalities and geographies. Companies that combine sharp asset targeting with agile execution will secure the best opportunities






